Secaucus – October 19, 2026 -- A broader set of lab criteria identified primary aldosteronism (PA) in 26.2% of 60,449 U.S. patients, twice the 13.0% flagged under the Endocrine Society's 2025 guidelines, according to a Quest Diagnostics (NYSE: DGX) study published in the journal Hypertension.

Secaucus, N.J. – September 18, 2026 -- A new national survey commissioned by Quest Diagnostics (NYSE: DGX) finds that 75% of 1,024 registered voters surveyed consider diagnostic lab testing "very important" to their care, with a bipartisan majority pressing Congress to pass the RESULTS Act before scheduled Medicare payment cuts take effect January 1, 2027.